Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,054 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物关于2025年年度报告的信息披露监管问询函的回复公告
Regulatory Filings Classification · 90% confidence The document is a detailed response from Shanghai Junshi Biosciences to an information‐disclosure inquiry letter issued by the Shanghai Stock Exchange regarding the company’s 2025 annual report. It is not the annual report itself, nor an earnings release, management change notice, or other specific category—it is a regulatory correspondence. As such, it falls under the general Regulatory Filings category (RNS).
2026-05-22 Chinese
国泰海通证券股份有限公司关于上海君实生物医药科技股份有限公司2025年年度报告的信息披露监管问询函回复的核查意见
Regulatory Filings Classification · 90% confidence The document is a sponsor (Guotai Haitong Securities) reply letter providing verification opinions in response to a Shanghai Stock Exchange information‐disclosure inquiry on the company’s 2025 Annual Report. It is not the Annual Report itself, an audit report, earnings release, or presentation, but rather a regulatory response filing. It falls under the general “Regulatory Filings” category (RNS).
2026-05-22 Chinese
容诚会计师事务所（特殊普通合伙）关于上海君实生物医药科技股份有限公司2025年年度报告的信息披露监管问询函的专项说明
Regulatory Filings Classification · 87% confidence The document is an auditor’s special explanatory letter (“专项说明”) in response to a regulatory inquiry (“监管问询函”) from the Shanghai Stock Exchange concerning the company’s 2025 annual report. It is not the annual report itself (10-K), nor a presentation (AGM-R, IP), nor an earnings release (ER), nor a financial supplement (XLSX). It is a compliance/response filing to a regulator’s inquiry, fitting the “Regulatory Filings” catch-all category (RNS).
2026-05-22 Chinese
君实生物自愿披露关于特瑞普利单抗一线治疗HER2表达的尿路上皮癌的新适应症上市申请获得批准的公告
Regulatory Filings Classification · 90% confidence The document is a voluntary corporate announcement filed on the Shanghai exchange regarding regulatory approval of a new drug indication. It contains details of the NMPA approval, drug study results, certificates, and risk warnings, but contains no financial statements, no proxy materials, no dividends, no earnings, and no management or interim report. It is a general regulatory announcement, so it falls under Regulatory Filings (RNS).
2026-05-21 Chinese
君实生物H股公告
Regulatory Filings
2026-05-07 Chinese
君实生物关于2025年度计提资产减值准备的公告
Regulatory Filings
2026-03-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.